Subtopic Deep Dive
Sexual Dysfunction and Cardiovascular Disease
Research Guide
What is Sexual Dysfunction and Cardiovascular Disease?
Sexual Dysfunction and Cardiovascular Disease examines the bidirectional relationship between erectile dysfunction and cardiovascular conditions through shared endothelial and vascular mechanisms.
Erectile dysfunction (ED) often precedes cardiovascular events by 2-3 years, serving as an early marker due to common endothelial dysfunction (Solomon et al., 2003; Montorsi et al., 2006). Studies identify organic causes in 15-72% of men under 40, shifting from psychogenic assumptions (Ludwig and Phillips, 2013). Over 10 key papers, with Ludwig and Phillips (2013) at 2154 citations, link ED to risk factors like diabetes and metabolic syndrome.
Why It Matters
ED predicts coronary artery disease onset, enabling early cardiovascular screening; Montorsi et al. (2006) COBRA trial shows ED precedes CAD by 2-3 years in most patients. PDE5 inhibitors like sildenafil treat both ED and pulmonary hypertension while addressing endothelial dysfunction (Ghofrani et al., 2006; Andersson, 2018). Low testosterone in obesity and type 2 diabetes heightens both sexual dysfunction and CVD risk, supporting integrated prevention (Wang et al., 2011). Lindau and Gavrilova (2010) quantify sexually active life years gained via health improvements.
Key Research Challenges
Quantifying Bidirectional Causality
Distinguishing whether ED causes CVD progression or vice versa remains unresolved despite cohort data. Montorsi et al. (2006) COBRA trial links ED timing to CAD extent but lacks longitudinal controls. Solomon et al. (2003) highlight endothelial overlap without causal models.
Endothelial Mechanism Specificity
Isolating shared pathways from confounders like smoking and diabetes challenges validation. Brunner et al. (2005) detail endothelial dysfunction in risk factors but note variable mechanisms. Lewis et al. (2004) epidemiology identifies risks without pathway granularity.
Therapeutic Translation Gaps
PDE5 inhibitors improve ED but inconsistent CVD outcomes require better biomarkers. Andersson (2018) reviews pharmacology yet calls for trial data. Wang et al. (2011) ties testosterone to risks without intervention efficacy.
Essential Papers
Organic Causes of Erectile Dysfunction in Men Under 40
Wesley Ludwig, Michael Phillips · 2013 · Urologia Internationalis · 2.2K citations
There are a significant number of men under 40 who experience erectile dysfunction (ED). In the past, the vast majority of cases were thought to be psychogenic in nature. Studies have identified or...
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*
Hanspeter Brunner, John Cockcroft, John Deanfield et al. · 2005 · Journal of Hypertension · 743 citations
Dysfunction of the vascular endothelium is a hallmark of most conditions that are associated with atherosclerosis and is therefore held to be an early feature in atherogenesis. However, the mechani...
Epidemiology/Risk Factors of Sexual Dysfunction
Ronald W. Lewis, Kersten S. Fugl-Meyer, Ramón Bosch et al. · 2004 · The Journal of Sexual Medicine · 640 citations
ABSTRACT Introduction Accurate estimates of prevalence/incidence are important in understanding the true burden of male and female sexual dysfunction and in identifying risk factors for prevention ...
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Hossein Ardeschir Ghofrani, Ian H. Osterloh, Friedrich Grimminger · 2006 · Nature Reviews Drug Discovery · 589 citations
Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing
Stacy Tessler Lindau, Natalia S. Gavrilova · 2010 · BMJ · 516 citations
Sexual activity, good quality sexual life, and interest in sex were higher for men than for women and this gender gap widened with age. Sexual activity, quality of sexual life, and interest in sex ...
Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator
H Solomon, J W Man, G Jackson · 2003 · Heart · 435 citations
Erectile dysfunction (ED) is a common condition and studies predict that it will become even more common in the future. There is increasing evidence to suggest that it is predominantly a vascular d...
PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery
K‐E. Andersson · 2018 · British Journal of Pharmacology · 426 citations
The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases. Since the discovery and introd...
Reading Guide
Foundational Papers
Start with Ludwig and Phillips (2013) for organic ED prevalence in young men, then Solomon et al. (2003) for endothelial-CVD links as ED marker; Brunner et al. (2005) details vascular mechanisms.
Recent Advances
Wang et al. (2011) on testosterone in diabetes-CVD-ED; Andersson (2018) on PDE5 clinical applications.
Core Methods
Epidemiology (Lewis et al., 2004), coronary angiography trials (Montorsi et al., 2006), population surveys (Lindau and Gavrilova, 2010), PDE5 pharmacology (Ghofrani et al., 2006).
How PapersFlow Helps You Research Sexual Dysfunction and Cardiovascular Disease
Discover & Search
Research Agent uses searchPapers and citationGraph on 'erectile dysfunction cardiovascular endothelial' to map 2154-citation Ludwig and Phillips (2013) as hub, revealing Montorsi et al. (2006) COBRA trial clusters; exaSearch uncovers diabetes links via Wang et al. (2011), findSimilarPapers expands to 50+ related endothelial papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract timing data from Montorsi et al. (2006), verifyResponse with CoVe cross-checks ED-CAD precedence claims against Brunner et al. (2005); runPythonAnalysis with pandas meta-analyzes prevalence from Lewis et al. (2004) cohorts, GRADE grading scores evidence as high for endothelial links.
Synthesize & Write
Synthesis Agent detects gaps in testosterone-CVD mediation post-Wang et al. (2011), flags contradictions between psychogenic vs. organic ED (Ludwig and Phillips, 2013); Writing Agent uses latexEditText for review drafting, latexSyncCitations integrates 10 papers, latexCompile generates figures, exportMermaid diagrams PDE5 pathways from Ghofrani et al. (2006).
Use Cases
"Meta-analyze ED prevalence in young men with CVD risks from listed papers"
Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas on Ludwig/Phillips 2013 + Lewis 2004 excerpts) → CSV of 15-72% organic rates with stats output.
"Draft LaTeX review on PDE5 inhibitors for ED and CVD"
Synthesis Agent → gap detection on Andersson 2018 + Ghofrani 2006 → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with synced refs and pathway figure.
"Find code for endothelial function modeling linked to ED papers"
Research Agent → paperExtractUrls on Brunner 2015 → Code Discovery → paperFindGithubRepo + githubRepoInspect → repo with NO/cGMP simulation scripts for vascular modeling.
Automated Workflows
Deep Research workflow scans 50+ ED-CVD papers via searchPapers, structures report with GRADE-scored sections on Montorsi et al. (2006) timing data. DeepScan 7-step analyzes Solomon et al. (2003) endothelial claims with CoVe verification and Python stats on risks. Theorizer generates hypotheses linking low testosterone (Wang et al., 2011) to CVD via literature synthesis.
Frequently Asked Questions
What defines Sexual Dysfunction and Cardiovascular Disease?
It studies bidirectional links where ED signals endothelial dysfunction and CVD risk 2-3 years early (Montorsi et al., 2006; Solomon et al., 2003).
What are key methods used?
Epidemiological cohorts (Lewis et al., 2004), clinical trials like COBRA (Montorsi et al., 2006), and endothelial assessments (Brunner et al., 2005).
What are seminal papers?
Ludwig and Phillips (2013, 2154 citations) on organic ED causes; Solomon et al. (2003, 435 citations) on ED as CVD marker.
What open problems persist?
Causal directionality, biomarker specificity for PDE5 response (Andersson, 2018), and testosterone intervention trials (Wang et al., 2011).
Research Sexual function and dysfunction studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sexual Dysfunction and Cardiovascular Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers